Polynucleotide encoding a sclerostin-binding antibody
원문보기
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
C07H-021/04
C12N-005/02
C12N-005/20
출원번호
US-0950094
(2010-11-19)
등록번호
US-8383801
(2013-02-26)
발명자
/ 주소
Paszty, Christopher J.
출원인 / 주소
Amgen Inc.
인용정보
피인용 횟수 :
1인용 특허 :
45
초록
Compositions and methods relating to epitopes of sclerostin protein, and sclerostin binding agents, such as antibodies capable of binding to sclerostin, are provided.
대표청구항▼
1. An isolated polynucleotide comprising a nucleotide sequence encoding a variable region of an antibody or fragment thereof that binds sclerostin of SEQ ID NO: 1, said variable region comprising (a) complementarity determining region (CDR)-H1 of SEQ ID NO:245, CDR-H2 of SEQ ID NO:246, and CDR-H3 of
1. An isolated polynucleotide comprising a nucleotide sequence encoding a variable region of an antibody or fragment thereof that binds sclerostin of SEQ ID NO: 1, said variable region comprising (a) complementarity determining region (CDR)-H1 of SEQ ID NO:245, CDR-H2 of SEQ ID NO:246, and CDR-H3 of SEQ ID NO:247 or (b) CDR-L1 of SEQ ID NO:78, CDR-L2 of SEQ ID NO:79 and CDR-L3 of SEQ ID NO:80, or both. 2. The polynucleotide of claim 1 comprising a nucleotide sequence encoding a light chain variable region comprising CDR-L1 of SEQ ID NO:78, CDR-L2 of SEQ ID NO:79, and CDR-L3 of SEQ ID NO:80. 3. The polynucleotide of claim 2, further comprising a nucleotide sequence encoding a light chain constant region. 4. The polynucleotide of claim 1 comprising a nucleotide sequence encoding a heavy chain variable region comprising CDR-H1 of SEQ ID NO:245, CDR-H2 of SEQ ID NO:246, and CDR-H3 of SEQ ID NO:247. 5. The polynucleotide of claim 4, further comprising a nucleotide sequence encoding an IgG4 or an IgG2 constant region. 6. The polynucleotide of claim 1, further comprising a nucleotide sequence encoding a light chain and/or heavy chain constant region. 7. The polynucleotide of claim 1, wherein the antibody or fragment demonstrates a binding affinity (Kd) for sclerostin of SEQ ID NO: 1 of less than or equal to about 10−7 M. 8. The polynucleotide of claim 1, wherein the antibody is a human antibody, a humanized antibody, or a chimeric antibody. 9. The polynucleotide of claim 1, wherein the antibody is a monoclonal antibody. 10. The polynucleotide of claim 1, wherein the antibody comprises an F(ab′)2, Fab, Fab′, Fv, Fc, or Fd fragment. 11. A cloning or expression vector comprising one or more polynucleotide sequences according to claim 1. 12. The vector of claim 11, wherein the vector comprises at least one polynucleotide sequence set forth in SEQ ID NO:134, 136, 138, 140, 142, 144, 146, 148, 377, and 379. 13. A host cell comprising one or more cloning or expression vectors according to claim 11. 14. A host cell comprising one or more cloning or expression vectors according to claim 12. 15. A polynucleotide comprising a nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 378. 16. The polynucleotide of claim 15, wherein the nucleotide sequence encodes a heavy chain of SEQ ID NO:145 or 392. 17. A cloning or expression vector comprising the polynucleotide of claim 15. 18. A polynucleotide comprising a nucleotide sequence encoding the amino acid sequence set forth in SEQ ID NO: 376. 19. The polynucleotide of claim 18, wherein the nucleotide sequence encodes a light chain of SEQ ID NO: 141. 20. A cloning or expression vector comprising the polynucleotide of claim 18. 21. A host cell comprising the polynucleotide of claim 15 and the polynucleotide of claim 18. 22. A host cell comprising the polynucleotide of claim 16 and the polynucleotide of claim 19. 23. A process for producing an antibody or fragment thereof, comprising culturing the host cell of claim 13 and isolating the antibody or fragment. 24. A process for producing an antibody or fragment thereof, comprising culturing the host cell of claim 14 and isolating the antibody or fragment. 25. A process for producing of an antibody or fragment thereof, comprising culturing the host cell of claim 21 and isolating the antibody or fragment. 26. A process for producing of an antibody or fragment thereof, comprising culturing the host cell of claim 22 and isolating the antibody or fragment.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (45)
Btzow Ralf (Helsinki CA FIX) Ruoslahti Erkki (Rancho Santa Fe CA), 60 kDa transforming growth factor-b
상세보기
Brunkow, Mary E.; Galas, David J.; Kovacevich, Brian; Mulligan, John T.; Paeper, Bryan W.; Van Ness, Jeffrey; Winkler, David G., Antibodies associated with alterations in bone density.
Dan Michael D.,CAX ; Maiti Pradip K.,CAX ; Kaplan Howard A.,CAX, Antigen binding fragments that specifically detect cancer cells, nucleotides encoding the fragments, and use thereof for the prophylaxis and detection of cancers.
Mary E. Brunkow ; David J. Galas ; Brian Kovacevich ; John T. Mulligan ; Bryan W. Paeper ; Jeffrey Van Ness ; David G. Winkler, Compositions and methods for increasing bone mineralization.
Ladner Robert C. (Ijamsville MD) Guterman Sonia K. (Belmont MA) Roberts Bruce L. (Milford MA) Markland William (Milford MA) Ley Arthur C. (Newton MA) Kent Rachel B. (Boxborough MA), Directed evolution of novel binding proteins.
Yagi Kunio (Aichi-ken JPX) Noda Hitoshi (Aichi-ken JPX) Ohishi Nobuko (Gifu JPX) Kurono Masayasu (Mie-ken JPX), Liposome for entrapping gene, liposomal preparation and process for the manufacture of the preparation.
Stemmer Willem P. C. ; Crameri Andreas, Methods for generating polynucleotides having desired characteristics by iterative selection and recombination.
Margolis David J. (Philadelphia PA), Methods of treating osteoporosis, increasing bone mineral content and preventing the occurrence of compression fractures.
Mary E. Brunkow ; David J. Galas ; Brian Kovacevich ; John T. Mulligan ; Bryan W. Paeper ; Jeffrey Van Ness ; David G. Winkler, Nucleic acids encoding a novel family of TGF-.beta. binding proteins from humans.
Mary E. Brunkow ; David J. Galas ; Brian Kovacevich ; John T. Mulligan ; Bryan W. Paeper ; Jeffrey Van Ness ; David G. Winkler, Polypeptides associated with alterations in bone density.
Liversidge Gary G. (West Chester PA) Cundy Kenneth C. (Pottstown PA) Bishop John F. (Rochester NY) Czekai David A. (Honeoye Falls NY), Surface modified drug nanoparticles.
Goldenberg Milton D. (11837 Gainsborough Rd. Potomac MD 20854), Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.